Top-News
Biotechnologie USA

Regulus Therapeutics Inc Aktie

Aktie
WKN:  A3DNZ4 ISIN:  US75915K3095 US-Symbol:  RGLS
7,845 $
-0,005 $
-0,06%
6,9408 € 02.05.25
Depot/Watchlist
Aktienanzahl *
66,24 Mio.
Marktkapitalisierung *
460,65 Mio. €
Streubesitz
11,13%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 25.04.2025

Regulus Therapeutics Inc News

06.05.24 - PR Newswire
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney ...
30.04.24 - PR Newswire
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series PR Newswire
21.03.24 - PR Newswire
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates PR Newswire
12.03.24 - PR Newswire
Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew?
Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew? PR Newswire
12.03.24 - PR Newswire
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity PR Newswire
02.01.24 - PR Newswire
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients ...
22.11.23 - PR Newswire
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire
09.11.23 - PR Newswire
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates PR Newswire
19.10.23 - PR Newswire
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney ...
20.09.23 - PR Newswire
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the ...
13.09.23 - PR Newswire
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients ...
05.09.23 - PR Newswire
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire
23.08.23 - PR Newswire
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 PR Newswire
08.08.23 - PR Newswire
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates PR Newswire
02.08.23 - PR Newswire
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference PR Newswire
18.07.23 - PR Newswire
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference PR Newswire
27.06.23 - PR Newswire
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal ...
23.06.23 - PR Newswire
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors PR Newswire
20.06.23 - PR Newswire
Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital ...
12.06.23 - PR Newswire
Regulus Therapeutics Strengthens Research & Development Leadership
Regulus Therapeutics Strengthens Research & Development Leadership PR Newswire

Newssuche

Videos

newspaper
30.04.25 +22,47%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »